Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Access Pharmaceuticals has reported initial data from an ongoing ovarian cancer study utilizing ProLindac at two and three week intervals. It found a reduction of the Ca125 biomarker in five of the six patients in the cohort receiving the higher dose of ProLindac on a once every three week dosing schedule.
Subscribe to our email newsletter
The reduction in Ca125 biomarker provides an early sign that a treatment regimen is effective in combating ovarian cancer. At the reported doses, toxic effects observed were generally mild and ProLindac displayed none of the acute neurotoxicity associated with other approved DACH platinum compounds.
Stephen Seiler, president and CEO of Access, said: “We are very pleased by the activity and safety of ProLindac in the early cohorts of the ovarian cancer trial. Even as we continue dose escalation in the current trial, existing results have given us sufficient confidence to move forward with the execution of additional development plans for ProLindac and we have already commenced manufacturing drug supply for several further clinical trials, including combination trials, which we plan to commence beginning next year.”